Related Experiment Video
Updated: Aug 20, 2026

Integration of Light Trapping Silver Nanostructures in Hydrogenated Microcrystalline Silicon Solar Cells by Transfer Printing
Published on: November 9, 2015
Su-11248 Sugen
1Division of Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1752, USA. kms@ucla.edu
Abstract:
SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.
Insights
SUGEN is developing SU-11248, an oral tyrosine kinase (TK) inhibitor targeting platelet-derived growth factor and other TK pathways for cancer treatment. Phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were ongoing in October 2003.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tyrosine kinase (TK) signaling pathways play a critical role in cancer cell proliferation and survival.
- Inhibitors targeting TKs are a promising strategy for anticancer drug development.
- SU-11248 is an orally active small molecule designed to inhibit multiple TKs.
Purpose of the Study:
- To evaluate SU-11248, an orally active tyrosine kinase inhibitor, as a potential anticancer therapeutic.
- To assess the efficacy of SU-11248 in patients with gastrointestinal stromal tumors (GIST) and renal cell carcinoma (RCC).
Main Methods:
- Development of SU-11248, an orally active inhibitor targeting platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways.
- Initiation of Phase III clinical trials to evaluate SU-11248 in patients with GIST and RCC.
Main Results:
- By October 2003, Phase III trials for gastrointestinal stromal tumors were underway.
- By October 2003, Phase III trials for renal cell carcinoma were underway.
Conclusions:
- SU-11248 demonstrates potential as an anticancer agent targeting key TK signaling pathways.
- Ongoing Phase III trials will determine the clinical utility of SU-11248 for GIST and RCC treatment.
Related Concept Videos
Dimensional Analysis
Conversion Factors and Dimensional Analysis
The unit...
Precipitation Reactions
Bond Energies and Bond Lengths
Titration Calculations: Weak Acid - Strong Base
For the titration of 25.00 mL of 0.100 M CH3CO2H with 0.100 M NaOH, the reaction can be represented as:
Standard Entropy Change for a Reaction
Electrolysis

